Literature DB >> 21629623

Adnexal masses and malignancies of importance to the colorectal surgeon.

Richard C Kline1, Lisa B Bazzett-Matabele.   

Abstract

In this article, the authors review both benign and malignant ovarian masses, as the colorectal surgeon who encounters an adnexal mass at the time of surgery should be aware of the steps necessary for surgical staging and optimal tumor resection.Ovarian tumors-most of which are benign-are divided into three major categories, in order of frequency: epithelial, germ cell, and sex cord-stromal tumors. Nonneoplastic conditions of the ovary that may present as adnexal masses include the following, according to World Health Organization (WHO) classification: pregnancy luteoma, hyperplasia of ovarian stroma, hyperthecosis, massive edema, solitary follicle cysts and corpus luteal cysts, multiple follicle cysts, and endometriosis.Epithelial ovarian tumors arise from the surface epithelium and can be benign or malignant. Histologic types are serous, mucinous, endometrioid, clear cell, or Brenner. Germ cell tumors are more likely to appear in females under 20 years, accounting for 70% of ovarian tumors in this age group. Approximately 3% are malignant. Teratomas are the most common germ cell tumors. Malignancies, in addition to malignant teratomas, include dysgerminomas, endodermal sinus tumors, and embryonal carcinomas. The more common sex cord-stromal tumors include granulosa stromal cell tumors, Sertoli-Leydig cell tumors, and gynandroblastomas.Surgical staging and optimal tumor resection are also addressed, with a focus on epithelial malignancies, as they are the most relevant to colorectal surgeons.

Entities:  

Keywords:  Adnexal masses; ovarian cancer; ovarian cysts

Year:  2010        PMID: 21629623      PMCID: PMC2967325          DOI: 10.1055/s-0030-1254292

Source DB:  PubMed          Journal:  Clin Colon Rectal Surg        ISSN: 1530-9681


  16 in total

1.  Complications associated with intraperitoneal chemotherapy catheters.

Authors:  S Makhija; M Leitao; P Sabbatini; N Bellin; L Almadrones; L Leon; D R Spriggs; R Barakat
Journal:  Gynecol Oncol       Date:  2001-04       Impact factor: 5.482

2.  Prognostic significance of tumor cell morphometry, histopathology, and clinical parameters in advanced ovarian carcinoma.

Authors:  C Ludescher; A R Weger; J Lindholm; D Oefner; H Hausmaninger; R Reitsamer; G Mikuz
Journal:  Int J Gynecol Pathol       Date:  1990       Impact factor: 2.762

Review 3.  Prognostic significance of pathologic features of ovarian carcinoma.

Authors:  S G Silverberg
Journal:  Curr Top Pathol       Date:  1989

4.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

Authors:  Deborah K Armstrong; Brian Bundy; Lari Wenzel; Helen Q Huang; Rebecca Baergen; Shashikant Lele; Larry J Copeland; Joan L Walker; Robert A Burger
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

Review 5.  Management of adnexal masses in postmenopausal women.

Authors:  J R van Nagell; P D DePriest
Journal:  Am J Obstet Gynecol       Date:  2005-07       Impact factor: 8.661

Review 6.  Conservative surgery for borderline ovarian tumors: a review.

Authors:  Raffaele Tinelli; Andrea Tinelli; Francesco G Tinelli; Ettore Cicinelli; Antonio Malvasi
Journal:  Gynecol Oncol       Date:  2005-10-10       Impact factor: 5.482

7.  Ovarian cancer: patterns of surgical care across the United States.

Authors:  Barbara A Goff; Barbara J Matthews; Michelle Wynn; Howard G Muntz; Denise M Lishner; Laura-Mae Baldwin
Journal:  Gynecol Oncol       Date:  2006-09-26       Impact factor: 5.482

8.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

9.  Staging laparotomy in early ovarian cancer.

Authors:  R C Young; D G Decker; J T Wharton; M S Piver; W F Sindelar; B K Edwards; J P Smith
Journal:  JAMA       Date:  1983-12-09       Impact factor: 56.272

10.  Results from four rounds of ovarian cancer screening in a randomized trial.

Authors:  Edward Partridge; Aimee R Kreimer; Robert T Greenlee; Craig Williams; Jian-Lun Xu; Timothy R Church; Bruce Kessel; Christine C Johnson; Joel L Weissfeld; Claudine Isaacs; Gerald L Andriole; Sheryl Ogden; Lawrence R Ragard; Saundra S Buys
Journal:  Obstet Gynecol       Date:  2009-04       Impact factor: 7.623

View more
  2 in total

1.  Geminin Is Essential for Pluripotent Cell Viability During Teratoma Formation, but Not for Differentiated Cell Viability During Teratoma Expansion.

Authors:  Diane C Adler-Wailes; Joshua A Kramer; Melvin L DePamphilis
Journal:  Stem Cells Dev       Date:  2016-11-07       Impact factor: 3.272

2.  Selective elimination of pluripotent stem cells by PIKfyve specific inhibitors.

Authors:  Arup R Chakraborty; Alex Vassilev; Sushil K Jaiswal; Constandina E O'Connell; John F Ahrens; Barbara S Mallon; Martin F Pera; Melvin L DePamphilis
Journal:  Stem Cell Reports       Date:  2022-01-20       Impact factor: 7.294

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.